Research funding

Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain Amyloidosis

Alexion Pharmaceuticals (ALXN) has been one of the greatest growth stories in the ultra-rare disease space over the past decade, with their blockbuster C5 inhibitor…

Pfizer - Linkedin

@amyloidosisfoundation

@Amyloidosisfdn

Supporting #amyloidosis patients and families while promoting research, education and awareness.

Subscribe to

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Learn More

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion